OPUS 4 | Search

23 search hits

1 to 20

Sort by

Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 × 2, phase II trial (2020)

Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine (2025)

In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also in patients with adverse-risk genetics, without adding toxicity. We performed a post hoc analysis to determine the predictive impact of TP53 status. Despite a nominally higher ORR, the clinically meaningful survival benefit when adding ATRA to DEC was diminished, but not completely negated, in TP53-mutated patients. Indeed, 2 out of 14 TP53-mutated patients (14%) randomized to a DEC + ATRA-containing regimen lived for > 36 months. Further studies of ATRA combined with hypomethylating agents appear warranted in non-M3 AML patients ineligible for HMA/venetoclax therapy.

Randomized phase II study of all-trans retinoic acid and valproic acid added to decitabine in newly diagnosed elderly AML patients (DECIDER trial): predictive impact of TP53 status [Abstract] (2021)

Results of the randomized phase II study decider (AMLSG 14-09) comparing decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) add-on in newly diagnosed elderly non-fit AML patients [Abstract] (2016)

Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response (2021)

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 (2023)

Kayser, Sabine ; Martínez-Cuadrón, David ; Hanoun, Maher ; Stölzel, Friedrich ; Gil, Cristina ; Reinhardt, H. Christian ; Aguiar, Eliana ; Schäfer-Eckart, Kerstin ; Burgues, Juan Miguel Bergua ; Steffen, Björn ; Bernal, Teresa ; Krause, Stefan W. ; Riaza, Rosalía ; Schliemann, Christoph ; Cervera, Jose ; Kaufmann, Martin ; Torres-Miñana, Laura ; Hänel, Mathias ; Acuña-Cruz, Evelyn ; Jost, Edgar ; Algarra, Jesus Lorenzo ; Crysandt, Martina ; Fransecky, Lars ; Cornago-Navascues, Javier ; Kraus, Sabrina ; Martinez-Lopez, Joaquin ; Einsele, Hermann ; Niemann, Dirk ; Neubauer, Andreas ; Seggewiß-Bernhardt, Ruth ; Scholl, Sebastian ; Klein, Stefan A. ; Schmid, Christoph ; Schaich, Markus ; Schmidt-Hieber, Martin ; Zukunft, Sven ; Ho, Anthony D. ; Platzbecker, Uwe ; Baldus, Claudia D. ; Müller-Tidow, Carsten ; Thiede, Christian ; Bornhäuser, Martin ; Serve, Hubert ; Levis, Mark ; Montesinos, Pau ; Röllig, Christoph ; Schlenk, Richard F.

Comprehensive genomic characterization of refractory multiple myeloma reveals a complex mutational and structural landscape associated with drug resistance [Abstract] (2017)

Lehners, Nicola ; Toprak, Umut H. ; Xu, Jing ; Paramasivam, Nagarajan ; Hübschmann, Daniel ; Fröhlich, Martina ; Hanafiah, Nur H. Md. ; Mughal, Sadaf ; Mai, Elias K. ; Jauch, Anna ; Hillengass, Jens ; Eils, Roland ; Müller-Tidow, Carsten ; Brors, Benedikt ; Goldschmidt, Hartmut ; Schlesner, Matthias ; Raab, Marc S.

Single versus double induction with "7+3" containing 60 versus 90 mg Daunorubicin for newly diagnosed AML: results from the randomized controlled SAL Dauno-double trial [Abstract] (2022)

Venetoclax-based salvage therapy improves outcome in relapsed/refractory AML patients eligible for intensive treatment: a propensity score matching analysis [Abstract] (2022)

Double-blind, placebo controlled, randomized, multicenter, phase II study to assess the efficacy of the high affinity CXCR4 inhibitor BL-8040 as addition to consolidation therapy in AML by the ASL and OSHO Leukemia Study Groups [Abstract] (2022)

Jaramillo Segura, Sonia ; Wass, Maxi ; Schaffrath, Judith ; Rieger, Kathrin ; Nogai, Axel ; Hänel, Mathias ; Herbst, Regina ; Stölzel, Friedrich ; Röllig, Christoph ; Jost, Edgar ; Schlenk, Richard F. ; Noppeney, Richard ; Brandts, Christian H. ; Krug, Utz ; Götze, Katharina S. ; Buske, Sebastian ; Florschütz, Axel ; Schubert, Jörg ; Opitz, Bernhard ; Mohren, Martin ; Eßeling, Eva ; von Witzendorff, Stephan ; Subklewe, Marion ; Kaufmann, Martin ; Frickhofen, Norbert ; Scholz, Christian W. ; Schäfer-Eckart, Kerstin ; Kunzmann, Volker ; Schmidt-Hieber, Martin ; Sayer, Herbert G. ; Rank, Andreas ; Hemmati, Philipp ; Schüler, Frank ; Kowoll, Simone ; Scheller, Marina ; Steighardt, Jörg ; Edemir, Bayram ; Müller, Lutz Peter ; Gliko-Kabir, Irit ; Ludwig-Kraus, Beatrice ; Edemir, Sabine ; Sorani, Ella ; Binder, Mascha ; Vainstein, Abi ; Kadosh, Shaul ; Gromann, Cora ; Wienke, Andreas ; Baldus, Claudia D. ; Platzbecker, Uwe ; Serve, Hubert ; Bornhäuser, Martin ; Junghanss, Christian ; Müller-Tidow, Carsten

Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML (2021)

Validation of a proxy‐reported SARC‐F questionnaire for current and retrospective screening of sarcopenia‐related functional impairments (2021)

Maurus, Johannes ; Terzer, Tobias ; Benner, Axel ; Goisser, Sabine ; Eidam, Annette ; Roth, Anja ; Janssen, Maike ; Jaramillo, Sonia ; Lorenz, Hannes Martin ; Micol, William ; Hauer, Klaus ; Müller‐Tidow, Carsten ; Bauer, Jürgen M. ; Jordan, Karin ; Neuendorff, Nina Rosa

Venetoclax-Azacitidine as salvage therapy and bridge to allogeneic cell transplantation in relapsed/refractory AML compared to historical data of the SAL registry study (2021)

1 to 20